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Abstract
Objectives
Our objectives were to describe trends in enrolment and clinical outcomes in the open, pro-
spective Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) in the Morogoro region of
southern Tanzania, and identify strengths and areas for improvement in the care of HIV-pos-
itive individuals in rural Tanzania.
Methods
We included adults (15 years) and children (<15 years) enrolled in the cohort in 2005–
2014. The cohort underwent significant changes from autumn 2012 to optimise care. We
evaluated mortality and loss to follow-up (LTFU) using competing risks methods, ART
usage, opportunistic infections (OI), co-infections and laboratory abnormalities.
Results
Overall, 7010 adults and 680 children were enrolled; enrolment peaked in 2008 but has
increased steadily since 2011. Among adults (65% female; median age 37 [interquartile
range 31–45] years), the proportion referred from hospital wards quadrupled in 2013–14
versus earlier years. 653 (9%) adults died and 2648 (38%) were LTFU; the five-year cumu-
lative probabilities of death and LTFU were 10.3% and 44.0%, respectively. Among children,
69 (10%) died and 225 (33%) were LTFU. The corresponding five-year probabilities were
12.1% and 39.6%. Adult ART use (regardless of eligibility) increased from 5% in 2005 to
89% in 2014 (similarly among children), with 9% on second-line therapy in 2014 (17% of
children). OI diagnoses increased over time; tuberculosis prevalence at enrolment
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quadrupled from 6% in 2011 to 26% in 2014. The proportion of newly-enrolled participants
assessed for laboratory abnormalities peaked at nearly 100% in 2014 (from a minimum of
24%), yet abnormality prevalences remained fairly constant.
Conclusions
In this cohort, ART usage improved dramatically and is approaching targets of 90%.
Improved screening led to increases in detection of OIs and laboratory abnormalities, sug-
gesting that a large number of these co-morbidities previously went undetected and
untreated. Further work will address the high LTFU rates and implications for mortality esti-
mates, and the management and outcomes of co-morbidities.
Introduction
The burden of the HIV epidemic in Tanzania is large, with an estimated 1.5 million adults and
children living with HIV in 2012 [1]. The national HIV/AIDS programme was launched in
2004 in response to the rising epidemic [2]. In 2004, the Chronic Diseases Clinic of Ifakara
(CDCI) was established within the St Francis Referral Hospital (SFRH), which serves over
600,000 people in the Kilombero and Ulanga districts of the Morogoro region in southern
Tanzania [3]. The CDCI was the first rural HIV care and treatment clinic accredited to provide
HIV services through the National AIDS Control programme (NACP). Within the framework
of the CDCI, a prospective, open cohort was initiated in 2005 by the Ifakara Health Institute,
in collaboration with the Swiss Tropical & Public Health Institute and the University Hospital
Basel. The Kilombero and Ulanga Antiretroviral Cohort (KIULARCO), with systematic data
collection on clinical parameters including antiretroviral therapy (ART) use, co-morbidities
and clinical outcomes such as opportunistic infections (OIs) and mortality, plus a plasma bio-
bank spanning ten years, has become a unique research platform.
Since autumn 2012, significant changes have been made at the CDCI targeting education of
the clinical staff, optimisation of the patient circuit, implementation of routine diagnostic tests,
better integration of HIV services with other units and SFRH wards, and an extensive overhaul
of data collection along with the launch of comprehensive electronic medical records. Early
evidence suggests that implementation of this broad bundle of services has improved the
running of the clinic and enhanced care, such as through earlier and better detection of tuber-
culosis co-infection [4]. Despite recommendations of increasing CD4 thresholds for ART initi-
ation, most people living with HIV in Tanzania still present late in the course of HIV disease.
Late presentation is associated with higher prevalence of OIs and non-AIDS co-morbidities,
incidence of immune reconstitution inflammatory syndrome (IRIS) after ART initiation, rate
of hospitalisations, use of healthcare resources, and mortality [5–7]. Thus, pre-ART screening
of OIs and co-morbidities is a key component to improving outcomes in sub-Saharan Africa.
Since 2012, a systematic screening of tuberculosis, cryptococcosis, hepatitis B, syphilis, and
renal and liver disease is performed at the CDCI prior to ART initiation.
The aim of this paper is to present the trends over the ten-year data collection period in
enrolment and retention in HIV care, mortality, ART usage, and rates of detection of OIs, co-
infections and laboratory abnormalities. Our results give a comprehensive overview of the
cohort, contribute to the currently-limited knowledge of comorbidities among HIV-positive
persons in Tanzania, and identify strengths and areas for improvement in the care of HIV-pos-
itive individuals in rural Tanzania.
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Methods
Study design and population
The CDCI, through the NACP, offers free HIV care and treatment services. Attendees are
those identified as HIV-positive following presentation for voluntary counselling and testing
(VCT) or through provider-initiated counselling and testing (PITC) while admitted to the
SFRH wards, or those who have transferred in from another clinic; all are invited to participate
in KIULARCO. For this analysis of prospectively-collected cohort data, we included all
patients enrolled from 2005 to 2014, except patients who refused consent; HIV-negative
patients; transit patients (enrolled in other clinics but who attended CDCI temporarily, usually
for a drug refill while travelling); and patients with missing enrolment or birth dates. We
included longitudinal data through to 31 December 2014.
Clinic procedures and data capture
Since autumn 2012, a number of changes to HIV services were implemented at the CDCI to
optimise care. Changes included introduction of PITC in the SFRH wards, and screening of
OIS and non-AIDS co-morbidities, including improvements in tuberculosis detection and
care with integration of the tuberculosis clinic within the CDCI [4,8]. Routine enrolment
screening services now include hepatitis B, syphilis and, for patients with CD4 count <150
cells/mm3, cryptococcal antigenaemia using cryptococcal antigen (CRAG) lateral flow assay
(IMMY, Norman, Oklahoma) [9]. A One Stop Clinic was created to provide dedicated care for
HIV-positive pregnant women, children and their families [10] and HIV pro-viral DNA PCR
was implemented for early infant diagnosis.
Since May 2013, the CDCI is paperless; new comprehensive data capture forms were trans-
lated into an electronic medical record system where patient data are entered directly during
their visit. At registration, we capture sociodemographic data and medical history. During
clinical visits, we record vital signs and laboratory results, perform a structured physical exami-
nation to determine working diagnoses (captured through ICD-10 codes [11]), and assess
treatment adherence, failure and toxicity, and IRIS. ART, cotrimoxazole prophylaxis, isoniazid
preventive treatment and fluconazole prophylaxis for CRAG-positive patients are prescribed
electronically and dispensed from the clinic pharmacy to the patient or treatment supporter.
Visits are scheduled at least every 3 months for those on ART and every 6 months for those
not yet on ART.
Diagnosis of OIs, IRIS, co-infections and laboratory abnormalities
among adults
For this study, tuberculosis diagnosis was defined as positive microscopy with acid-fast bacilli,
positive Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) in sputum or other extra pul-
monary sample, chest radiograph suggestive of tuberculosis plus at least one symptom, taking
anti-tuberculosis medication, or physician diagnosis. Cryptococcosis, Kaposi’s sarcoma, Pneu-
mocystis jirovecii pneumonia (PCP), toxoplasmosis, non-Hodgkin’s lymphoma and bacterial
pneumonia were physician-diagnosed, with cryptococcosis confirmed by CRAG-positive in
plasma and cryptocococcal meningitis in cerebrospinal fluid. IRIS, as diagnosed by the clini-
cian, was categorised as suspected, probable or definite adapting commonly-accepted case def-
initions [12–15]. Syphilis was diagnosed by Venereal Disease Research Laboratory test and
hepatitis B by one surface antigen test. Severe anaemia was defined as haemoglobin <8 g/dL
[16], liver impairment as alanine transaminase >256 U/L (where 56 U/L is the upper limit of
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normal) [17], and renal impairment as creatinine clearance <90 ml/min/1.73m2, calculated
using the Chronic Kidney Disease Epidemiology Collaboration equation [18].
Statistical methods
Analyses are presented for adults (age15 years at enrolment) and children (<15 years), by
enrolment year. After assessing data distributions, similar time periods were grouped together,
which also corresponded with changes in cohort leadership. We present participant character-
istics at enrolment using appropriate summary statistics. We evaluated the number and pro-
portion of individuals on ART according to first (non-nucleoside reverse transcriptase
inhibitor-based) or second line (boosted protease inhibitor-based) therapy, and we describe
ART initiations among adults. We assessed mortality and lost to follow-up (LTFU), defined as
>60 days passed since their next planned visit [19]. Participants who had not died, were not
LTFU and had not transferred out were considered to be in follow-up to 31 December 2014.
We estimated time to death or LTFU using competing risks methods [20], with results pre-
sented as cumulative incidences and 95% confidence intervals (CI).
Among adults, we evaluated tuberculosis prevalence at enrolment (diagnosed within the
first month of enrolment, which may have been previously diagnosed outside of the clinic)
and incidence amongst those not positive at enrolment. We evaluated other OI diagnoses fol-
lowing a CD4 count<200 cells/mm3. We assessed the testing and diagnosis of laboratory
abnormalities within one month of enrolment.
Analyses were performed using Stata version 13 (StataCorp. 2013. Stata Statistical Software:
Release 13. College Station, TX: StataCorp LP).
Ethical statement
The Ifakara Health Institute Institutional Review Board and the National Health Research
Ethics Review Committee of the National Institute for Medical Research of Tanzania provide
ethical approval for KIULARCO, including for sample collection, cryopreservation and retro-
spective analysis. Written informed consent is sought from all participants at registration at
the CDCI; for children and adolescents aged <18 years, informed consent is sought from their
caregivers. Those who refused consent were excluded from our analyses. Individualised clini-
cal consultations take place in separate rooms at the CDCI, to ensure privacy. Patient-friendly
schedules are followed, and each clinician has an assigned pool of patients to improve patient
satisfaction and compliance. All data analysed for this study, including laboratory results from
samples, were captured under routine care at the CDCI; data are stored on a secure server and
were de-identified before analysis.
Results
Cohort enrolment
Of 10,191 individuals, we excluded 1569 (15%) who refused participation, 15 (<1%) subse-
quently identified as HIV-negative, 779 (8%) transit patients, 121 (1%) who were missing
enrolment date and 17 (<1%) who were missing date of birth. Therefore, we included 7010
adults and 680 children in the analysis (S1 Fig). At least 400 participants were enrolled every
year since 2005, with a peak in 2008 and a further steady increase over recent years (Fig 1A).
Participant characteristics at enrolment
The adult sociodemographic characteristics remained fairly stable over time (Table 1), with
42% residing in Ifakara, where the CDCI is situated. Patients mostly came to the CDCI via
A decade of HIV care in rural Tanzania: Impact of clinic optimisation
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Fig 1. Enrolment and ART usage over time. A) Enrolment. B) ART usage among adults. C) ART usage
among children. Adults15 years; children <15 years. Participants on ART at any point in a given year were
classified as on ART. Denominator is patients with any clinical or drug visit in a given year. Percentages may
not add up to 100% due to rounding. Percentages <1% are not shown.
https://doi.org/10.1371/journal.pone.0180983.g001
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Table 1. Demographic and clinical characteristics of adults (15 years) at enrolment (n = 7010).
Year of enrolment
2005–07 2008–09 2010–12 2013–14 Total
Number enrolled 1827 (100%) 2351 (100%) 1611 (100%) 1221 (100%) 7010 (100%)
Ward
Ifakara 632 (35.7%) 880 (37.8%) 901 (56.3%) 498 (40.9%) 2911 (42.1%)
Mngeta 139 (7.9%) 272 (11.7%) 74 (4.6%) 208 (17.1%) 693 (10.0%)
Mang’ula 118 (6.7%) 231 (9.9%) 58 (3.6%) 69 (5.7%) 476 (6.9%)
Mlimba 80 (4.5%) 213 (9.1%) 9 (0.6%) 46 (3.8%) 348 (5.0%)
Othera 800 (45.2%) 735 (31.5%) 557 (34.8%) 397 (32.6%) 2489 (36.0%)
Distance from home to clinic, kmb 2 (1–70) 25 (1–81) 1 (1–20) 5 (1–51) 1 (1–51)
Patient referred fromc
Voluntary counselling and testing or self-referral 956 (52.3%) 1925 (81.9%) 1223 (75.9%) 863 (70.7%) 4967 (70.9%)
Reproductive and child health clinic 69 (3.8%) 113 (4.8%) 136 (8.4%) 53 (4.3%) 371 (5.3%)
Out-patient department 254 (14.6%) 45 (2.0%) 47 (3.1%) 15 (1.2%) 361 (5.4%)
In-patient care hospitalisation (PITC) 24 (1.6%) 75 (3.4%) 47 (3.1%) 125 (10.2%) 271 (4.2%)
Transfer in 0 (0.0%) 31 (1.3%) 44 (2.7%) 213 (17.4%) 288 (4.1%)
Tuberculosis or DOTS 86 (4.7%) 50 (2.1%) 47 (2.9%) 3 (0.2%) 186 (2.7%)
Other 105 (5.7%) 40 (1.7%) 56 (3.5%) 27 (2.2%) 228 (3.3%)
Sex, female 1194 (65.4%) 1509 (64.2%) 1038 (64.5%) 816 (66.9%) 4557 (65.0%)
Marital status, married/cohabiting 800 (48.4%) 1197 (51.6%) 805 (50.7%) 758 (62.2%) 3560 (52.5%)
Education, none/primary school only 497 (94.7%) 766 (94.9%) 805 (93.4%) 1151 (94.3%) 3219 (94.3%)
Age, years 37 (31–44) 37 (31–45) 37 (31–45) 37 (31–45) 37 (31–45)
Pregnantd 26 (3.7%) 62 (6.6%) 88 (10.0%) 76 (10.3%) 252 (7.7%)
Partner status, HIV-positivee 118 (69.4%) 313 (66.2%) 239 (62.6%) 239 (71.3%) 909 (66.8%)
Disclosure of HIV status toc
Partner 60 (3.4%) 152 (6.6%) 354 (24.0%) 358 (38.5%) 924 (14.2%)
Relative 41 (2.3%) 183 (7.9%) 475 (32.1%) 599 (64.5%) 1298 (20.0%)
Time from HIV diagnosis to enrolment, months 1.6 (0.5–7.4) 0.5 (0.1–1.3) 0.3 (0.1–0.5) 0.1 (0.0–0.5) 0.4 (0.1–2.0)
BMI, kg/m2
Underweight (<18.5) 229 (29.6%) 216 (27.9%) 294 (20.6%) 262 (22.6%) 1001 (24.2%)
Normal weight (18.5-<25) 451 (58.3%) 458 (59.1%) 866 (60.7%) 703 (60.7%) 2478 (59.9%)
Overweight (25-<30) 75 (9.7%) 83 (10.7%) 212 (14.9%) 143 (12.3%) 513 (12.4%)
Obese (30) 18 (2.3%) 18 (2.3%) 55 (3.9%) 51 (4.4%) 142 (3.4%)
WHO stage
I 596 (38.1%) 779 (33.5%) 653 (41.7%) 433 (39.9%) 2461 (37.6%)
II 246 (15.7%) 666 (28.7%) 347 (22.1%) 160 (14.8%) 1419 (21.7%)
III 448 (28.6%) 603 (25.9%) 431 (27.5%) 296 (27.3%) 1778 (27.2%)
IV 275 (17.6%) 276 (11.9%) 136 (8.7%) 195 (18.0%) 882 (13.5%)
CD4 count, cells/mm3
<50 85 (15.7%) 216 (14.1%) 117 (14.0%) 179 (17.4%) 597 (15.1%)
50–99 81 (14.9%) 180 (11.7%) 98 (11.7%) 123 (12.0%) 482 (12.2%)
100–199 119 (21.9%) 319 (20.8%) 155 (18.6%) 183 (17.8%) 776 (19.7%)
200–349 117 (21.5%) 322 (21.0%) 188 (22.5%) 219 (21.3%) 846 (21.5%)
350–499 55 (10.1%) 222 (14.5%) 129 (15.4%) 141 (13.7%) 547 (13.9%)
(Continued )
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VCT or self-referral, but in-patient referrals (diagnosed through PITC) and transfers-in rose
significantly in 2013–14 while out-patient referrals dropped after 2005–07. The majority of
participants were female (65%), were married/cohabiting (53%) and only had at most primary
school education (94%). The median (interquartile range [IQR]) age was 37 (31–45) years.
Reported disclosure of HIV status to partners and relatives increased respectively from 3% and
2% in 2005–07 to 39% and 65% in 2013–14. Over the same time period, the median time from
reported HIV diagnosis to enrolment decreased from 1.6 months (IQR 0.5–7.4) to 0.1 months
(0.0–0.4). Trends toward lower WHO stage at enrolment reversed in 2013–14, approaching
2005–07 levels (41% WHO stage III/IV overall), while the proportion of patients with CD4
count<350 cells/mm3 remained fairly stable after 2005–07 (69% overall).
Among children, the median age at enrolment decreased, from 6 (IQR 3–9) years in 2005–
07 to 4 years (1–8) in 2013–14, as did the time from HIV diagnosis to enrolment (from 1.0
(0.2–5.4) to 0.1 (0.0–0.5) months; Table 2). Over the same time periods, the percentage of chil-
dren with WHO stage III/IV increased (from 47% to 77%).
ART usage
Overall, 4989 (71%) adults and 513 (75%) children ever received ART under the care of the
CDCI, of whom 484 (10%) and 41 (8%), respectively, had prior ART exposure. Of adults
attending the CDCI in any given year, the percentage of patients on ART (regardless of eligibil-
ity) rapidly increased from 5% in 2005 to at least 80% since 2010 (Fig 1B), with similar patterns
among children (Fig 1C). The proportion of adults on second line therapy increased from
none pre-2008 to 9% in 2014, while the proportion of children on second line therapy
increased rapidly from1% pre-2012 to 17% in 2014. Among 361 adults not on ART in 2014,
191 (53%) were not yet eligible for therapy. Of the remaining 170 adults, 132 (37%) had been
under follow-up for<90 days, 1 (<1%) did not have eligibility information captured, and 37
(22%) had been under follow-up for at least 90 days and were eligible for ART but had not yet
started.
ART initiations among adults
Overall, 4502 adults initiated ART (excluding women starting for prevention of mother-to-
child HIV transmission) for the first time at the CDCI (Table 3). In 2005–2007, 70% of patients
Table 1. (Continued)
Year of enrolment
2005–07 2008–09 2010–12 2013–14 Total
500 86 (15.8%) 277 (18.0%) 148 (17.7%) 183 (17.8%) 694 (17.6%)
Results are median (interquartile range) for continuous variables and number (column % of non-missing data) for categorical variables. Variables with >10%
missing data: distance from home to clinic (17% missing, since not all wards mapped), education (51% missing, mainly from earlier years), BMI (41%
missing, mainly due to missing height), CD4 count (44% missing, mainly from earlier years). CD4 count and WHO stage at enrolment were defined as the
measurement closest to the date of enrolment, within -24 to +4 weeks (preference for earlier). BMI, body mass index; DOTS, directly observed treatment,
short course; PITC, provider-initiated testing and counselling.
aEstimated based on ward of residence.
bWards with <10% of participants each have been combined.
cParticipants may respond yes to more than one category.
dPercentages are of women with non-missing data (missing for 28% women).
ePercentages are of those with results (excluding 81% not applicable/missing).
https://doi.org/10.1371/journal.pone.0180983.t001
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Table 2. Demographic and clinical characteristics of children (<15 years) at enrolment (n = 680).
Year of enrolment
2005–07 2008–09 2010–12 2013–14 Total
Number enrolled 166 (100%) 244 (100%) 150 (100%) 120 (100%) 680 (100%)
Sex, female 72 (43.4%) 115 (47.1%) 74 (49.3%) 56 (46.7%) 317 (46.6%)
Age, years 6 (3–9) 4 (2–8) 5 (2–9) 4 (1–8) 5 (2–8)
Age <5 years 69 (41.6%) 141 (57.8%) 79 (52.7%) 68 (56.7%) 357 (52.5%)
Time from HIV diagnosis to enrolment, months 1.0 (0.2–5.4) 0.3 (0.0–1.3) 0.2 (0.1–1.2) 0.1 (0.0–0.5) 0.3 (0.0–1.6)
WHO stage
I 49 (34.0%) 84 (35.9%) 47 (32.2%) 20 (17.2%) 200 (31.3%)
II 28 (19.4%) 71 (30.3%) 28 (19.2%) 7 (6.0%) 134 (20.9%)
III 39 (27.1%) 66 (28.2%) 54 (37.0%) 50 (43.1%) 209 (32.7%)
IV 28 (19.4%) 13 (5.6%) 17 (11.6%) 39 (33.6%) 97 (15.2%)
CD4 <25% 55 (87.3%) 113 (72.4%) 49 (62.8%) 82 (75.9%) 299 (73.8%)
Results are median (interquartile range) for continuous variables and number (column % of non-missing data) for categorical variables. Variables with >10%
missing data: CD4% (40% missing, mainly from earlier years). CD4 count and WHO stage at enrolment were defined as the measurement closest to the
date of enrolment, within -24 to +4 weeks (preference for earlier).
https://doi.org/10.1371/journal.pone.0180983.t002
Table 3. Characteristics of adults (15 years) at ART initiation.
Year of ART initiation
2005–07 2008–09 2010–12 2013–14 Total
Number initiated ART 679 (100%) 1547 (100%) 1358 (100%) 918 (100%) 4502 (100%)
Time from enrolment to ART initiation, monthsa 4.7 (0.9–12.6) 1.0 (0.2–4.1) 0.5 (0.1–8.1) 0.5 (0.2–2.5) 0.9 (0.2–6.2)
ART regimen started
d4T+3TC+NVP 474 (69.8%) 915 (59.1%) 160 (11.8%) 0 (0.0%) 1549 (34.4%)
d4T+3TC+EFV 22 (3.2%) 45 (2.9%) 9 (0.7%) 0 (0.0%) 76 (1.7%)
AZT+3TC+NVP 7 (1.0%) 22 (1.4%) 125 (9.2%) 53 (5.8%) 207 (4.6%)
AZT+3TC+EFV 172 (25.3%) 503 (32.5%) 490 (36.1%) 118 (12.9%) 1283 (28.5%)
TDF+FTC+EFV 0 (0.0%) 0 (0.0%) 239 (17.6%) 352 (38.3%) 591 (13.1%)
TDF+3TC+EFV 0 (0.0%) 0 (0.0%) 0 (0.0%) 382 (41.6%) 382 (8.5%)
Other first line 0 (0.0%) 0 (0.0%) 3 (0.2%) 3 (0.3%) 6 (0.1%)
Second line (boosted PI-based) 2 (0.3%) 0 (0.0%) 7 (0.5%) 10 (1.1%) 19 (0.4%)
Otherb 2 (0.3%) 62 (4.0%) 325 (23.9%) 0 (0.0%) 389 (8.6%)
CD4 count at initiation, cells/mm3
<100 134 (26.7%) 412 (35.8%) 208 (26.4%) 249 (31.1%) 1003 (31.0%)
100–199 162 (32.3%) 355 (30.9%) 187 (23.7%) 166 (20.8%) 870 (26.9%)
200–349 125 (25.0%) 262 (22.8%) 262 (33.2%) 236 (29.5%) 885 (27.3%)
350–499 45 (9.0%) 66 (5.7%) 74 (9.4%) 91 (11.4%) 276 (8.5%)
500 35 (7.0%) 55 (4.8%) 58 (7.4%) 58 (7.2%) 206 (6.4%)
Results are median (interquartile range) for continuous variables and number (column % of non-missing data) for categorical variables. Variables with >10%
missing data: CD4 count (26%, 26%, 42% and 16% missing in 2005–07, 2008–09, 2010–12, 2013–14, respectively). CD4 count at ART initiation was
defined as the measurement closest to the date of initiation, within-24 to +4 weeks (preference for earlier). d4T, stavudine; 3TC, lamivudine; NVP,
nevirapine; EFV, efavirenz; AZT, zidovudine; TDF, tenofovir disoproxil fumarate; FTC, emtricitabine.
aThis table is restricted to participants who were observed to initiate ART, and therefore does not take into account participants who were not (yet) observed
to initiate ART.
bRegimen unknown therefore not possible to classify as first or second line.
https://doi.org/10.1371/journal.pone.0180983.t003
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initiated on stavudine, lamivudine and nevirapine. Over time, efavirenz replaced nevirapine,
the backbone of tenofovir disoproxil fumarate with emtricitabine or lamivudine became more
common (80% of initiations in 2013–14), and stavudine was phased out, in line with national
guidelines [21]. There were some albeit small increases over time in the proportion of partici-
pants initiating ART with CD4 count350 cells/mm3, at 16%, 11%, 17% and 19% in 2005–07,
2008–09, 2010–12 and 2013–14, respectively.
Mortality and loss to follow-up
Over approximately 18,000 person-years at risk, 653 (9%) adults died and 2648 (38%) were
LTFU (S1 Fig). By five years after enrolment, the cumulative probability of death was 10.3%
(95% CI 9.5–11.1) and LTFU was 44.0% (42.7–45.4). By year of registration, the probabilities
of reported death at 12 months after enrolment were 11.6% (10.2–13.1), 6.3% (5.4–7.4), 3.0%
(2.2–3.9) and 5.2% (3.9–6.8) among those registered in 2005–07, 2008–09, 2010–12 and 2013–
14, respectively (Fig 2A). The corresponding values for LTFU were 22.0% (20.1–24.0), 26.5%
(24.7–28.4), 26.7% (24.5–28.9) and 21.9% (19.0–24.9; Fig 2B).
Over approximately 1900 person-years at risk, 69 (10%) children died and 225 (33%) were
LTFU (S1 Fig). By five years after enrolment, the cumulative probability of death was 12.1%
(9.5–15.1) and LTFU was 39.6% (35.2–43.9). Over the same time periods as above, the proba-
bilities of reported death by 12 months after enrolment were 8.2% (4.6–13.1), 8.4% (5.3–12.3),
1.4% (0.3–4.5) and 9.4% (4.7–15.9), respectively (Fig 2C). The corresponding values for LTFU
were 19.0% (13.3–25.5), 23.3% (18.1–28.8), 19.1% (13.1–26.0) and 12.3% (5.5–22.1; Fig 2D).
Fig 2. Incidence of death and loss to follow up (LTFU). A) Adults: Death by enrolment year. B) Adults:
LTFU by enrolment year. C) Children: Death by enrolment year. D) Children: LTFU by enrolment year. Adults
15 years; children <15 years. Analysis by competing risks. Participants were considered LTFU if more than
60 days had passed since their next planned visit (based on next appointment date, or otherwise assumed to
be every 3 months for those on ART and every 6 months for those not yet on ART, not including those known
to have died or transferred out). Only the first 12 months since enrolment are shown (since little further follow-
up was available for those enrolled in 2013–14), and the y-axes are truncated at 0.5.
https://doi.org/10.1371/journal.pone.0180983.g002
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Fig 3. Tuberculosis and laboratory abnormalities at enrolment among adults (15 years). A) Diagnosis
of tuberculosis. B) Testing and diagnosis of severe anaemia. C) Testing and diagnosis of liver impairment. D)
Testing and diagnosis of renal impairment. For tuberculosis, values show the percentage of diagnoses within
the CDCI (within the first month following enrolment; these OIs may have been previously diagnosed outside
of the clinic; with denominator the number of participants who had a clinical visit within the first month following
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Among both adults and children, the earliest that one can meet the LTFU definition is two
months after the next planned visit (Fig 2B and 2D). The larger increases in LTFU at 8 months
among adults enrolled in some of the enrolment years are attributable to those who did not
start ART at enrolment and did not return to the clinic for a follow-up visit. Among 6515
adults who were ART-naïve before enrolment, the percentage starting ART within 2 weeks of
enrolment increased over time (from 7% in 2005–07 to 41% in 2013–14), and those starting
ART within this period were less likely to be LTFU within the first year after enrolment than
those not starting ART (20% versus 25%; Χ2 test, p<0.001). Across all participants, 902 (12%)
had a gap in care of>1 year before re-engaging in care (ie returning for a clinic visit), and 487
(6%) had a gap of>2 years.
Opportunistic infections and IRIS among adults
The prevalence of tuberculosis diagnosis among adults at enrolment peaked at 11% in 2008,
declined and then rapidly increased after 2012 to 26% in 2014 (Fig 3A). Among those without
tuberculosis at enrolment, the incidence peaked at 8% in 2008 and has remained at 2–4% since
then.
Before 2011, diagnoses of disseminated cryptococcosis, Kaposi sarcoma and PCP were
often not recorded; among adults with results captured at their first CD4 count <200 cells/
mm3, the annual prevalences were typically <1%. However, in 2014, the prevalences were
5.0%, 3.6% and 5.8%, respectively. Toxoplasmosis, non-Hodgkin’s lymphoma and bacterial
pneumonia were not consistently recorded before 2013; the prevalences among adults with
first CD4 count<200 cells/mm3 in 2014 were 2.2%, 0.5% and 8.9%, respectively.
IRIS detection was low pre-2013 (5 diagnoses per year), and increased to 39 (1.7% of
adults on ART without previous IRIS) and 49 (1.9%) diagnoses in 2013 and 2014, respectively.
In 2013–14, the classification of diagnoses was 58 suspected, 18 probable and 11 definite.
Co-infections among adults
Few syphilis presumptive diagnoses were made before 2014 (12 per year), but 133 new diag-
noses were made in 2014 (16% of adults with a visit and not previously positive). Hepatitis B
was not routinely captured before 2013, but as the result of a screening initiative in 2014, 199
(7%) new diagnoses of chronic hepatitis B were made in 2014 [22].
Laboratory abnormalities among adults
The proportion of newly-enrolled participants assessed for laboratory abnormalities peaked in
2014 following implementation of routine screening, approaching 100% coverage (96%, 87%
and 97% for anaemia, liver impairment and renal impairment, respectively; Fig 3B–3D). Prev-
alences of severe anaemia, liver impairment and renal impairment remained between 11–18%,
1–4% and 6–15%, respectively, despite large increases in the proportion tested.
enrolment in that year). For laboratory tests, no tests were performed in 2005 and few in 2006 therefore these
years were omitted. A window of-24 to +4 weeks relative to registration date was allowed, with preference for
before. Severe anaemia defined as haemoglobin <8 g/dL [16]. Liver impairment defined as alanine
transaminase >2*56 U/L, ie twice the upper limit of normal [17]. Renal impairment defined as creatinine
clearance <90 ml/min/1.73m2, calculated using the Chronic Kidney Disease Epidemiology Collaboration
equation [18].
https://doi.org/10.1371/journal.pone.0180983.g003
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Discussion
In this comprehensive longitudinal analysis of a prospective cohort spanning 10 years and
including nearly 8000 HIV-positive patients, we found that a bundle of measures aiming to
improve patient care have led to better linkage to care within the hospital, shortening of time
between diagnosis and enrolment, increases in ART usage, improved screening of OIs, and
higher testing and detection of laboratory abnormalities.
Until 2011, the CDCI observed enrolment patterns similar to national trends [2], but there-
after–in contrast to national trends–enrolment began to steadily increase. We attribute the
recent increases to the 2014 implementation of consistent PITC in the medical, paediatric and
tuberculosis wards, and the out-patient department of SFRH; average monthly enrolment
increased from 45 in 2013 to 67 in 2014. Similar enrolment patterns were observed in children,
despite being more difficult to diagnose and link to care [23]. The average monthly enrolment
increased from three children per month in April-December 2013 to eight in the same time
period in 2014 after the launch in early 2014 of the One Stop Clinic, and implementation of
PITC and HIV pro-viral DNA PCR for infant diagnosis. In recent years, we found that patients
were linking to care sooner following their HIV diagnosis, in part attributable to measures
such as the national VCT campaign in 2007–08 [24]. However, we did not observe corre-
sponding improvements in disease stage or CD4 count at enrolment, likely related to the
implementation of PITC capturing sicker patients, and suggesting that people are still waiting
too long to get tested and presenting late in the course of the disease. Our findings are in line
with the national data, where approximately 45% of people with a CD4 count result at enrol-
ment had <200 cells/mm3 [2].
ART usage increased dramatically over time, despite Tanzanian guidelines not recom-
mending universal ART initiation for those with CD4 counts >350 cells/mm3 at the time of
this study [25] and little evidence of changes in CD4 count distributions over time. Our
observed rates of ART usage of 89% among adults and 92% among children in 2014 are sub-
stantially higher than the reported national coverage (61% and 26% of eligible adults and chil-
dren, respectively, in 2012) [26] and are in line with UNAIDS treatment targets for 2020 [23].
At the CDCI in 2014, eligibility to start ART with respect to CD4 count was evaluated in 94%
of patients at enrolment compared to a maximum of 70% in earlier years and 27% nationwide
in 2011 [25], likely due to our improved clinic circuit and electronic data capture. This acceler-
ated process for evaluating eligibility should lead to reductions in loss to follow up, which was
25% by one year in those who did not start ART shortly after enrolment, suggesting they were
linked to but failed to remain in care. In light of the results of the START and TEMPRANO tri-
als [27,28], moving to a test-and-treat approach will not only lead to earlier engagement in
care, but dramatically improve patient outcomes.
Over time, the absolute numbers of diagnoses of OIs and laboratory abnormalities has
increased, most notably in 2013–14. This can be attributed to an increasing number of labora-
tory tests being performed–in part related to growth in equipment and expertise, policy
changes regarding screening at baseline, and improved medical evaluations, training and data
capture. Tuberculosis diagnoses at enrolment quadrupled from pre-2011 to 2014, most likely
attributable to improvements in detection rather than underlying changes in prevalence, and
indicating that infections may have remained undiagnosed in earlier years [4]. Systematic lab-
oratory-based CRAG screening among those with low CD4 count, followed by lumbar punc-
ture to detect meningitis, allowed reliable ascertainment of disseminated cryptococcosis and
cryptococcal meningitis [29]. Our observed prevalence in 2014 of 5% is consistent with other
studies (3–7.1% [30]). While globally the incidence of Kaposi sarcoma is decreasing with
increasing ART coverage [31,32], we observed increasing prevalence over time, reaching 3.6%
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among patients enrolled in 2014 with low CD4 count, most likely due to improved detection,
although the limitations of physician-diagnosis are known [33]. Among the same KIULARCO
patients, PCP prevalence was lower than in a recent meta-analysis of studies conducted
between 1995 and 2015 (5.8% versus 15.4%) but the authors found substantial heterogeneity
by time, clinical setting and diagnostic method [34]. Our prevalence was also lower than a
study from 2006 (10.4%), however this was in HIV-infected patients presenting with cough
[35]. Further, our estimates should be interpreted as upper limits, since diagnostic tools for the
etiologic diagnosis were not in place. Importantly, toxoplasmosis, non-Hodgkin’s lymphoma
and bacterial pneumonia were not investigated prior to 2012, and the number of diagnoses of
bacterial pneumonia in particular indicates that there was previously a large unrecognised and
hence untreated problem. Toxoplasmosis was suspected on the basis of focal palsies in patients
with low CD4 count, but rarely confirmed through image techniques such as CT scan, which
is not available in Ifakara. Some studies report declining incidence of non-Hodgkin’s lym-
phoma with increasing ART coverage [32], but a study from Uganda found increasing inci-
dence [31]; we observed low prevalence (<1%), which should be cautiously interpreted due to
the lack of histologic confirmation. In addition, bacterial pneumonia was not confirmed with
pneumococcal antigen or blood cultures but refers to acute respiratory infections with radio-
logic consolidation that responded to antimicrobial therapy.
Measuring haematological, renal and liver parameters can aid in choosing the most appro-
priate ART regimen to minimise drug toxicity; tenofovir disoproxil fumarate is associated
with renal impairment, zidovudine with haematological abnormalities, and nevirapine and
efavirenz with liver toxicity, among others [36–43]. In Tanzania, current guidelines recom-
mend haematological and biochemistry renal and liver function tests pre-ART and at ART ini-
tiation, and haemoglobin, creatinine and ALT monitoring for those on zidovudine, tenofovir
disoproxil fumarate and nevirapine respectively [44]. The associated financial burden is likely
to be a contributory factor for the high rates of early attrition in some African settings [45].
In the CDCI, these services are provided at no cost to the patient and coverage of baseline
laboratory testing increased significantly over time to reach approximately 90% in 2014. How-
ever, the prevalence of laboratory abnormalities did not change substantially. Based on this, we
estimate that there were 37, 3 and 22 undetected cases of severe anaemia, liver and renal
impairment at enrolment, respectively, in 2012 alone (representing 7%, 1% and 4% of adults
enrolled in that year, respectively).
The observed trends in death and LTFU are more difficult to interpret. There were clear dif-
ferences in the death rates by year of enrolment. In sub-Saharan Africa, the adult mortality
rate in the first year after treatment initiation is estimated to be in the range 8–26% [46], there-
fore the observed low rate in our cohort in 2010–12 in particular is implausible and suggests
that perhaps a large proportion of deaths were not being captured. One-year LTFU rates in
adults remained between 22–27% over time but showed trends toward improvement in 2013–
14. The higher observed death rate in children during the first months under care in 2013–14
can likely be attributed to the higher proportions presenting with WHO stage III/IV, due to
improved clinical assessment and higher proportions of children identified through PITC in
the hospital wards [10]. Our high LTFU rates are in line with similar cohorts [47] and may
partly be explained by silent transfers to other clinics [48]. Regardless, such LTFU presents
challenges in obtaining accurate mortality estimates. Time-dependent modelling taking into
account LTFU rates over time is the focus of on-going work [49].
The impact of the clinic changes has led to improvements in patient care across a broad
range of outcomes, and the benefits are felt by both staff and patients, with a decrease in lost
test results files and improved efficiency in running the clinic. However, the implementation
of these changes has not been without challenges. The increased ascertainment of HIV through
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the consistent implementation of PITC has led to an overburdened clinic with long waiting
times and intensified demand for human resources. Further, there is a shortage of skilled and
HIV-experienced healthcare workers and we face difficulties retaining them in peripheral
rural settings. Moreover, structural system barriers lead to frequent shortages of reagents, anti-
retrovirals and other drugs for OIs, thus impairing patients’ outcomes. Finally, developing and
maintaining an electronic medical record system in this setting has been hampered by limita-
tions in infrastructure, power cuts, and a lack of local technological expertise. Strengths of the
cohort are the large number of patients enrolled over the last decade, with the accompanying
biobank, and in recent years the data captured are extensive.
In summary, we have illustrated what can be achieved by a clinic delivering HIV care and
treatment services to a rural population of around 600,000 people. Since its inception over ten
years ago, the CDCI has undergone substantial changes; a number of improvements in patient
care and outcomes have already been observed but the full implications of the changes remain
to be seen. Future implementation of routine viral load monitoring and optimisation of patient
tracking will also improve care and provide a more accurate picture of impact. These develop-
ments and enhancements to data capture, allowing us to provide for example detailed data on
OIs and laboratory abnormalities for which there are limited reports, together with the bio-
bank, yield a rich resource which can be applied to address public health questions of direct
relevance to inform further improvements in patient care.
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